Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sara J. Gosline"'
Autor:
Jiawan Wang, Ana Calizo, Lindy Zhang, James C. Pino, Yang Lyu, Kai Pollard, Xiaochun Zhang, Alex T. Larsson, Eric Conniff, Nicolas Llosa, David K. Wood, David A. Largaespada, Susan E. Moody, Sara J. Gosline, Angela C. Hirbe, Christine A. Pratilas
Publikováno v:
bioRxiv
Malignant peripheral nerve sheath tumors (MPNST) are highly aggressive soft tissue sarcomas with limited treatment options, and novel effective therapeutic strategies are desperately needed. We observe anti-proliferative efficacy of genetic depletion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b141123c1fa8090bf92f019ef2924b2
https://doi.org/10.1101/2023.02.02.526674
https://doi.org/10.1101/2023.02.02.526674
Autor:
James C. Pino, Camilo Posso, Sunil K. Joshi, Michael Nestor, Jamie Moon, Joshua R. Hansen, Marina A. Gritsenko, Chelsea Hutchinson-Bunch, Karl K. Weitz, Kevin Watanabe-Smith, Jason E. McDermott, Brian J. Druker, Tao Liu, Jeffrey W. Tyner, Anupriya Agarwal, Elie Traer, Paul D. Piehowski, Cristina E. Tognon, Karin D. Rodland, Sara J. Gosline
Publikováno v:
Cancer Research. 83:3172-3172
Acute myeloid leukemia (AML) is a deadly blood cancer that remains largely classified by genetic aberrations, which inform therapy stratification. However, therapeutic response cannot be predicted or explained by genetic abnormalities alone. The inte
Autor:
Karl K. Weitz, Hutchinson-Bunch C, Rucha V. Modak, Sunil K. Joshi, Marina A. Gritsenko, Cristina E. Tognon, Drucker B, Anupriya Agarwal, Paul D. Piehowski, Karin D. Rodland, Jamie Moon, Hansen, Alisa Damnernsawad, Elie Traer, Sara J Gosline, Jason E. McDermott, Nestor M
Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31f0195ca82f2684b9e1e06b2576b3ad
https://doi.org/10.1101/2021.06.04.447154
https://doi.org/10.1101/2021.06.04.447154
Autor:
Guanming Wu, Sara J Gosline, Paul D. Piehowski, Ted Laderas, Shannon K. McWeeney, Alisa Damnernsawad, Tamilla Nechiporuk, Christopher A. Eide, Jeffrey W. Tyner, Anupriya Agarwal, Rucha V. Modak, Karin D. Rodland, Stephen E. Kurtz
Publikováno v:
Blood. 136:11-12
Background: The treatment of acute myeloid leukemia (AML) patients is a formidable challenge, due to disease heterogeneity and the ability to acquire secondary mutations in response to treatment. As a result, persistence and expansion of residual AML
Autor:
Özgün Babur, Kevin Watanabe-Smith, Liu Tao, Yi-Ting Wang, Angelo D'Alessandro, Daniel Bottomly, Shannon K. McWeeney, Tamilla Nechiporuk, Cristina E. Tognon, Karin D. Rodland, Paul D. Piehowski, Jamie Moon, Emek Demir, Janét Pittsenbarger, Sara J Gosline, Brian J. Druker, Elie Traer, Jeffrey W. Tyner, Julie A. Reisz, Andy Kaempf, Sunil K. Joshi
Publikováno v:
Blood. 136:4-5
Activating mutations in the tyrosine kinase receptor FLT3 are observed in ~35% of all acute myeloid leukemia (AML) cases. Multiple FLT3 inhibitors are currently in clinical development and while most patients initially respond well to FLT3 inhibition